We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quanterix Completes Acquisition of Akoya Biosciences

By LabMedica International staff writers
Posted on 09 Jul 2025

Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.

The integration of Akoya’s spatial biology capabilities in tissue with Quanterix’s advanced tools for the ultra-sensitive detection of biomarkers in blood establishes the first fully integrated technology ecosystem to identify and measure biomarkers across tissue and blood. Quanterix is better positioned to serve research customers and ultimately clinicians with a broader set of technologies to improve diagnostic relevance and accuracy and enhance patient outcomes through biomarker-driven treatment decisions. With Quanterix’s industry-leading position in neurology and Akoya’s focus within oncology and immunology, Quanterix can expand its technology offerings across these high-growth markets.


Image: The acquisition will add Akoya’s cutting-edge spatial biology capabilities to Quanterix’s portfolio (Courtesy of Akoya Biosciences)
Image: The acquisition will add Akoya’s cutting-edge spatial biology capabilities to Quanterix’s portfolio (Courtesy of Akoya Biosciences)

The addition of Akoya’s cutting-edge spatial biology capabilities enables Quanterix to capitalize on growth opportunities in a USD5 billion serviceable addressable market. Leveraging Akoya’s established clinical partnerships and CLIA-certified lab services, Quanterix is now strategically positioned to drive significant value creation through an expanded portfolio of lab service offerings. This collaboration establishes a clear path for Quanterix to participate in the rapidly emerging spatial biology clinical market, particularly in oncology. Quanterix and Akoya have complementary offerings and deep customer relationships across discovery, translational, and clinical research.

“The acquisition of Akoya positions us to deliver comprehensive protein biomarker solutions that leverage signatures in blood and tissue, together providing a more holistic and predictive view of a patient’s disease,” said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. “This transaction extends our portfolio into new markets and is expected to expand our served addressable market from USD 1 billion to USD 5 billion. We believe the combined business will benefit from significant scale, a strong balance sheet and an accelerated path to profitability by 2026.”

Related Links:
Quanterix Corporation
Akoya Biosciences


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Modular Hemostasis Automation Solution
CN Track

Latest Industry News

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
09 Jul 2025  |   Industry

AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
09 Jul 2025  |   Industry

Illumina Acquires SomaLogic to Accelerate Proteomics Business
09 Jul 2025  |   Industry



PURITAN MEDICAL